Elanco Animal Health Incorporated
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jeffrey N. Simmons
- Full Time Employees
- 9,900
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 450 Elanco Circle Indianapolis IN United States 46221
- IPO Date
- Sep 20, 2018
- CIK
- 0001739104
- Website
- elanco.com
- Similar Companies
- Business
- Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health that develops, manufactures, and markets innovative products and services to prevent and treat diseases in farm animals and pets. The company offers a comprehensive portfolio including parasiticides such as Credelio Quattro, Zenrelia, Advantage Family, and Seresto for pets; productivity enhancers like Experior and AdTab for cattle; vaccines, antibiotics, and feed additives for poultry and swine; and knowledge services providing data-driven insights to veterinarians, farmers, and pet owners worldwide. Elanco operates in over 100 countries with a focus on pet health and livestock sustainability segments, targeting veterinarians, farmers, pet owners, and food producers. Founded in 1954 as a division of Eli Lilly and Company and headquartered in Indianapolis, Indiana, Elanco spun off as an independent public company in 2018 and maintains manufacturing, research, and commercial operations globally. Recent strategic changes include the completed divestiture of its aqua business to Merck Animal Health for $1.3 billion in July 2024, enabling focus on core pet and farm animal growth areas; refinancing of a $2.1 billion Term Loan B facility in 2025 to extend maturities to 2032 and reduce interest costs; monetization of certain lotilaner U.S. royalties for $295 million in May 2025; and the opening of a new global headquarters in downtown Indianapolis. In third quarter 2025 results, Elanco reported organic constant currency revenue growth of 9%, driven by strong performances from Credelio Quattro (reaching $100 million in net sales within eight months), Zenrelia (global sales nearly doubling quarter-over-quarter with launches in the EU, Great Britain, and Australia), Experior (up 70% year-over-year), and AdTab (up over 25% year-over-year), while raising full-year 2025 guidance for revenue, innovation revenue, adjusted EBITDA, and adjusted EPS alongside an improved year-end net leverage ratio target of 3.7x to 3.8x.
Company News
Moderna, Humana and Elanco Earnings Previews: What Investors Should Watch
Elanco to Participate in UBS Global Healthcare Conference
Elanco Animal Health Incorporated (ELAN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Elanco Animal Health Appoints Jamie Preston as Chief People Officer
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Akamai Technolgies, Apple, Blackrock, Ford Motor, Healthcare Realty Trust, Noble, Sunoco LP, Venture Global, Western Midstream Partners, Zoetis, and More
Elanco Animal Health (NYSE:ELAN) Insider Timothy Bettington Sells 4,350 Shares of Company Stock
Will Elanco Animal Health (ELAN) Beat Estimates Again in Its Next Earnings Report?
Elanco Animal Health Eyes Growth, Deleveraging as Quattro and Zenrelia Gain Ground
State Street Corp Has $395.31 Million Holdings in Elanco Animal Health Incorporated $ELAN
Elanco Animal Health Incorporated (ELAN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Analyzing Amarin (NASDAQ:AMRN) & Elanco Animal Health (NYSE:ELAN)
Elanco Animal Health Incorporated $ELAN Shares Acquired by Corient Private Wealth LP
Elanco to Participate in BofA Securities Global Healthcare Conference 2026
Elanco Animal Health Incorporated (ELAN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Expanding Tick and Itch Season Supports Momentum in Elanco Innovation, Meeting Pet Owner Demand for Health and Wellness Care
Squarepoint Ops LLC Purchases New Position in Elanco Animal Health Incorporated $ELAN
Elanco Confirms Date and Conference Call for Third Quarter 2026 Financial Results Announcement
Elanco to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
Elanco Director Purchases 40,000 Shares for $936,000
Canada Pension Plan Investment Board Purchases New Holdings in Elanco Animal Health Incorporated $ELAN